Opioid agonist pharmacotherapy for the maintenance treatment of opioid dependence
30% of countries reported availability of opioid agonists (i.e. methadone, buprenorphine or buprenorphine/naloxone) for the maintenance treatment of opioid dependence in 2008. Coverage of the population in need appears to be low. Data of the ATLAS-SU report shows that in around 60% of low-income, lower middle-income and higher-middle income countries, opioid agonists for the maintenance therapy of opioid dependence is reaching less than 10% of opioid-dependent persons.